Publicacions en què col·labora amb LUIS CAMINAL MONTERO (21)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2020

  1. Erratum: Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus (Rheumatology (2020) 59 (1752-1764) DOI: 10.1093/rheumatology/keaa016)

    Rheumatology (United Kingdom)

  2. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile

    Rheumatology (Oxford, England), Vol. 59, Núm. 2, pp. 407-417

  3. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus

    Rheumatology (Oxford, England), Vol. 59, Núm. 7, pp. 1752-1764

  4. Relationship Between T-Cell Exosomes and Cellular Subsets in SLE According to Type I IFN-Signaling

    Frontiers in Medicine, Vol. 7

2019

  1. IRF4 and IRGS delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis

    Frontiers in Immunology, Vol. 10, Núm. JAN

2017

  1. Circulating microparticle subpopulations in systemic lupus erythematosus are affected by disease activity

    International Journal of Cardiology, Vol. 236, pp. 138-144

  2. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus

    Thrombosis and Haemostasis, Vol. 117, Núm. 11, pp. 2194-2206

  3. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. A pathogenic IFNα, BLyS and IL-17 axis in systemic lupus erythematosus patients

    Scientific Reports, Vol. 6

  2. Senescent profile of angiogenic T cells from systemic lupus erythematosus patients

    Journal of Leukocyte Biology, Vol. 99, Núm. 3, pp. 405-412

2014

  1. Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients

    Lupus, Vol. 23, Núm. 14, pp. 1477-1485

  2. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes

    Rheumatology (United Kingdom), Vol. 53, Núm. 12, pp. 2249-2258

2013

  1. Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus

    The Scientific World Journal, Vol. 2013

2008

  1. Lupus eritematoso sistémico o eclampsia

    Medicina Clinica

2007

  1. Leucoencefalopatía posterior reversible y lupus eritematoso sistémico

    Medicina Clinica

  2. Reversible Posterior Leukoencephalopathy or Leucoencephalopathy?

    Seminars in Arthritis and Rheumatism

1995

  1. Linfocitopenia CD4+ y sarcoidosis.

    Medicina Clinica

1992

  1. Esclerosis tuberosa: a propósito de un caso de presentación tardía.

    Revista Clinica Espanola

1991

  1. Hepatitis colestásica por cianamida.

    Revista Clinica Espanola